138 related articles for article (PubMed ID: 38342048)
1. Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma.
Kaira K; Imai H; Kagamu H
Lung Cancer; 2024 Mar; 189():107501. PubMed ID: 38342048
[No Abstract] [Full Text] [Related]
2. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.
Sato J; Satouchi M; Itoh S; Okuma Y; Niho S; Mizugaki H; Murakami H; Fujisaka Y; Kozuki T; Nakamura K; Nagasaka Y; Kawasaki M; Yamada T; Machida R; Kuchiba A; Ohe Y; Yamamoto N
Lancet Oncol; 2020 Jun; 21(6):843-850. PubMed ID: 32502444
[TBL] [Abstract][Full Text] [Related]
3. Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma.
Ito K; Yamaguchi O; Kaira K; Imai H; Kagamu H
Lung Cancer; 2023 May; 179():107193. PubMed ID: 37058785
[No Abstract] [Full Text] [Related]
4. Sustained antitumor response to lenvatinib with weekend-off and alternate-day administration in chemotherapy-refractory thymic carcinoma: a case report.
Sunaga N; Miura Y; Sakurai R; Ohshima S; Uno S; Muto S; Sato M; Tsurumaki H; Yatomi M; Koga Y; Ohtaki Y; Nagashima T; Okano N; Kubo N; Maeno T; Hisada T
Anticancer Drugs; 2023 Apr; 34(4):605-608. PubMed ID: 36729850
[TBL] [Abstract][Full Text] [Related]
5. Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma: A case report.
Matsumoto K; Shiroyama T; Miyake K; Yamamoto Y; Kuge T; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
Medicine (Baltimore); 2022 Jan; 101(1):e28476. PubMed ID: 35029896
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with lenvatinib in a patient with thymic carcinoma presenting with cardiac tamponade: a case report and review of literature.
Nakashima K; Azuma T; Ohta R; Fujii Y; Sato M; Igarashi K; Kadowaki M; Umeda Y; Waseda Y; Anzai M; Kobayashi M; Ishizuka T
Anticancer Drugs; 2022 Sep; 33(8):761-764. PubMed ID: 35946531
[TBL] [Abstract][Full Text] [Related]
7. The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma.
Romanos-Sirakis E; Doan A; Bittman ME; Webb RL; Williamson AK; Edelman M; Hanson D; Riely GJ; Fein Levy C
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e605-e608. PubMed ID: 34486558
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib for thymic carcinomas.
Takahashi N; Thomas A
Lancet Oncol; 2020 Jun; 21(6):745-746. PubMed ID: 32502438
[No Abstract] [Full Text] [Related]
11. Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report.
Terashima Y; Hakozaki T; Takeuchi S; Hosomi Y
Thorac Cancer; 2022 Dec; 13(23):3408-3411. PubMed ID: 36251511
[TBL] [Abstract][Full Text] [Related]
12. An Overview of the Use of Anti-Angiogenic Agents in the Treatment of Thymic Epithelial Tumors.
Agrafiotis AC; Berzenji L; Koyen S; Vermeulen D; Winthagen R; Hendriks JMH; Van Schil PE
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069386
[TBL] [Abstract][Full Text] [Related]
13. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
Remon J; Girard N; Novello S; de Castro J; Bigay-Game L; Bernabé R; Greillier L; Mosquera J; Cousin S; Juan O; Sampayo M; Besse B
Clin Lung Cancer; 2022 May; 23(3):e243-e246. PubMed ID: 34393061
[TBL] [Abstract][Full Text] [Related]
14. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
Antonarelli G; Corti C; Zucali PA; Perrino M; Manglaviti S; Lo Russo G; Varano GM; Salvini P; Curigliano G; Catania C; Conforti F; De Pas T
Eur J Cancer; 2022 Oct; 174():31-36. PubMed ID: 35970033
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B
Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035
[TBL] [Abstract][Full Text] [Related]
16. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G
Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
[TBL] [Abstract][Full Text] [Related]
18. When a thymic carcinoma "becomes" a GIST.
Rossi V; Donini M; Sergio P; Passalacqua R; Rossi G; Buti S
Lung Cancer; 2013 Apr; 80(1):106-8. PubMed ID: 23375402
[TBL] [Abstract][Full Text] [Related]
19. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.
Bisagni G; Rossi G; Cavazza A; Sartori G; Gardini G; Boni C
J Thorac Oncol; 2009 Jun; 4(6):773-5. PubMed ID: 19461405
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis.
Arunachalam A; Zhang I; Zhao B; Frederickson AM; Catherine Pietanza M
Lung Cancer; 2023 Feb; 176():132-139. PubMed ID: 36638588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
